Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis

AIM OF THE STUDY: Studies comparing atezolizumab plus bevacizumab (ATE/BEV) vs. lenvatinib (LEN) for advanced hepatocellular carcinoma (aHCC) have shown conflicting results. With this background, we aimed to collate the available evidence comparing ATE/BEV and LEN in aHCC. MATERIAL AND METHODS: A co...

Descripción completa

Detalles Bibliográficos
Autores principales: Giri, Suprabhat, Angadi, Sumaswi, Vaidya, Arun, Singh, Ankita, Roy, Akash, Sundaram, Sridhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544063/
https://www.ncbi.nlm.nih.gov/pubmed/37790692
http://dx.doi.org/10.5114/ceh.2023.130748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544063/
https://www.ncbi.nlm.nih.gov/pubmed/37790692
http://dx.doi.org/10.5114/ceh.2023.130748

Ejemplares similares